Targeted therapy of colorectal cancer: Clinical experience with bevacizumab

被引：53

作者：

Fernando, NH ^{[1
]}

Hurwitz, HI ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Dept Med Oncol & Transplantat, Durham, NC 27710 USA

来源：

ONCOLOGIST | 2004年 / 9卷

关键词：

colorectal cancer; clinical trial; bevacizumab; vascular endothelial growth factor; monoclonal antibodies;

D O I：

10.1634/theoncologist.9-suppl_1-11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advanced colorectal cancer remains an urgent health concern, despite improvements in systemic chemotherapy. Targeted therapeutics promise effective tumor therapy with minimal side effects. Angiogenesis (the formation of new blood vessels) is essential for tumor growth and metastasis and may be an ideal target in the search for new antineoplastic agents. Vascular endothelial growth factor is one of the best characterized of the proangiogenic growth factors that regulate angiogenesis and is a logical target in colorectal cancer therapy. Bevacizumab (Avastin(TM); Genentech Inc.; South San Fransisco, CA), a humanized murine monoclonal antibody directed at vascular endothelial growth factor, is being evaluated in the treatment of various types of cancer. It has shown promising efficacy in phase II clinical trials in patients with metastatic colorectal cancer. Addition of bevacizumab at a dose of 5 mg/kg to chemotherapy (5-fluorouracil plus leucovorin) resulted in a higher objective response rate (40% versus 17%), longer time to disease progression (9.0 versus 5.2 months), and longer median survival time (21.5 versus 13.8 months). Hypertension and thrombosis were the principal safety concerns, but were manageable. Further phase II/III studies of bevacizumab, administered with 5-fluorouracil plus leucovorin, with or without irinotecan and/or oxaliplatin, in colorectal cancer, are under way.

引用

页码：11 / 18

页数：8

共 40 条

[1]

BENSON AB, 2003, P AN M AM SOC CLIN, V22, P243

[2] Maximizing the potential of bevacizumab in cancer treatment [J].

Bergsland, E ;

Dickler, MN .

ONCOLOGIST, 2004, 9 :36-42

[3]

Borgström P, 1999, ANTICANCER RES, V19, P4203

[4] Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer [J].

Borner, MM ;

Dietrich, D ;

Stupp, R ;

Moran, R ;

Honegger, H ;

Wernli, M ;

Herrmann, R ;

Pestalozzi, BC ;

Saletti, P ;

Hanselmann, S ;

Müller, S ;

Brauchli, P ;

Castiglione-Gertsch, M ;

Goldhirsch, A ;

Roth, AD .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1759-1766

[5] Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer [J].

Chin, KF ;

Greenman, J ;

Gardiner, E ;

Kumar, H ;

Topping, K ;

Monson, J .

BRITISH JOURNAL OF CANCER, 2000, 83 (11) :1425-1431

[6] Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence [J].

Choi, HJ ;

Hyun, MS ;

Jung, GJ ;

Kim, SS ;

Hong, SH .

ONCOLOGY, 1998, 55 (06) :575-581

[7] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[8] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[9] Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site [J].

Fairbrother, WJ ;

Christinger, HW ;

Cochran, AG ;

Fuh, C ;

Keenan, CJ ;

Quan, C ;

Shriver, SK ;

Tom, JYK ;

Wells, JA ;

Cunningham, BC .

BIOCHEMISTRY, 1998, 37 (51) :17754-17764

[10] Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer [J].

Fernando, NH ;

Hurwitz, HI .

SEMINARS IN ONCOLOGY, 2003, 30 (03) :39-50

← 1 2 3 4 →